Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells

Cancer Gene Therapy

Volumn 18, Issue 7, 2011, Pages 467-477

  Kim, D R ^a,b   Park, M Y ^a,b   Lee, C S ^c   Shim, S H ^b   Yoon, H I ^a,b   Lee, J H ^a,b   Sung, M W ^b   Kim, Y S ^d   Lee, C T ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Inje University   (South Korea)

Author keywords

adenovirus TRAIL; CAR; transcription; transduction; vorinostat

Indexed keywords

CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PROTEIN BCL 2; PROTEIN KINASE B; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS RECEPTOR; VORINOSTAT;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; FLOW CYTOMETRY; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 79959380355     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.11     Document Type: Article

References (28)

1. Hemminki A, Alvarez RD. Adenoviruses in oncology: a viable option? BioDrugs 2002; 16: 77-87. (Pubitemid 34533769)
2. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323. (Pubitemid 27114163)
3. Jee YS, Lee SG, Lee JC, Kim MJ, Lee JJ, Kim DY et al. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 2002; 22: 2629-2634. (Pubitemid 36069290)
4. Wang Y, Wang S, Bao Y, Ni C, Guan N, Zhao J et al. Coxsackievirus and adenovirus receptor expression in nonmalignant lung tissues and clinical lung cancers. J Mol Histol 2006; 37: 153-160. (Pubitemid 44532065)
5. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75-83. (Pubitemid 32980246)
6. Lee CT, Seol JY, Park KH, Yoo CG, Kim YW, Ahn C et al. Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate. Clin Cancer Res 2001; 7: 210-214. (Pubitemid 32110225)
7. Dion LD, Goldsmith KT, Tang DC, Engler JA, Yoshida M, Garver Jr RI. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 1997; 231: 201-209. (Pubitemid 27244186)
8. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-1252. (Pubitemid 350106355)
9. VanOosten RL, Earel Jr JK, Griffith TS. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 2007; 12: 561-571.
10. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9: 440-451. (Pubitemid 46994573)
11. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006; 119: 944-954. (Pubitemid 44051462)
12. Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009; 45: 2425-2438.
13. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/ vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 2009; 8: 1596-1605.
14. Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW et al. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2003; 10: 540-548. (Pubitemid 36842011)
15. Lee CT, Lee YJ, Kwon SY, Lee J, Kim KI, Park KH et al. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27. Cancer Res 2006; 66: 372-377. (Pubitemid 43166044)
16. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol 2002; 21: 1161-1174.
17. Fan S, Maguire CA, Ramirez SH, Bradel-Tretheway B, Sapinoro R, Sui Z et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005; 125: 23-33. (Pubitemid 40298810)
18. Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S, Fojo T. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res 2003; 9: 5394-5401. (Pubitemid 37413595)
19. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP et al. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003; 63: 847-853. (Pubitemid 36231986)
20. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682. (Pubitemid 26091143)
21. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-563. (Pubitemid 28479189)
22. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886-2894. (Pubitemid 30660741)
23. Griffith TS, Stokes B, Kucaba TA, Earel Jr JK, VanOosten RL, Brincks EL et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9: 9-19.
24. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005; 280: 10025-10033. (Pubitemid 40395853)
25. Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008; 16: 1919-1926.
26. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006; 66: 5409-5418. (Pubitemid 43844968)
27. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-3236. (Pubitemid 29043975)
28. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-4471. (Pubitemid 36951018)